Opdivo nivolumab: Phase II data

Data from 80 evaluable patients with classical Hodgkin’s lymphoma who received Adcetris brentuximab vedotin after a failed autologous stem cell transplantation (ASCT) in the open-label, international Phase II CheckMate -205 trial showed that 3 mg/kg IV Opdivo every 2 weeks led to an IRRC-assessed ORR of 66%, including a complete remission rate of 8.8% and a partial remission rate of 57.5%. The IRRC-assessed 6-month PFS rate was 77% and the OS rate was 99%. Additionally, Opdivo led to an investigator-assessed ORR of 73%, including a complete remission rate of 27.5% and a partial remission rate of 45%. In 43 patients with no prior response to Adcetris, Opdivo led to an IRRC-assessed ORR of 72%. Data will be presented at the American Society of Clinical Oncology meeting in Chicago. ...